On April 8, 2025, MIRA Pharmaceuticals received a notice from Nasdaq stating it does not meet the minimum stockholders equity requirement of $2.5 million, with current equity at $2,199,750, but its stock will continue trading; the company has until May 23, 2025, to submit a compliance plan and is confident in regaining compliance, partly through a $5 million acquisition of SKNY Pharmaceuticals and ongoing clinical trials for its drug Ketamir-2.